Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Glenmark Life Sciences Ltd is a manufacturer of pharmaceutical preparation. The Company was founded in June 2011 and is located in Solapur, India.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has increased by 1.80%
Members of the Exchange are hereby informed that the name of Glenmark Life Sciences Limited shall be changed to Alivus Life Sciences Limited and symbol be changed to ALIVUS w.e.f. January 20, 2025. | Download
Members of the Exchange are hereby informed that the name of Glenmark Life Sciences Limited shall be changed to Alivus Life Sciences Limited and symbol be changed to ALIVUS w.e.f. January 20, 2025. | Download
Glenmark Life Sciences Limited has informed the Exchange that the name has been changed from 'Glenmark Life Sciences Limited' to 'Alivus Life Sciences Limited'. | Download
Glenmark Life Sciences Limited has informed the Exchange that the name has been changed from 'Glenmark Life Sciences Limited' to 'Alivus Life Sciences Limited'. | Download
Interim • Div/Share: ₹ 22.5
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 7.85%